Marimekko Corporation
18.9.2026 17:45:00 CEST | Globenewswire | Press release
Marimekko Corporation: Repurchase of own shares during week 38/2026
Marimekko Corporation: Repurchase of own shares during week 38/2026
Marimekko Corporation, Stock Exchange Release, 18 September 2026 at 6.45 p.m. EEST
Marimekko Corporation: Repurchase of own shares during week 38/2026
Marimekko Corporation has acquired its own shares during week 38 in the Helsinki Stock Exchange as follows:
| Trade date | Shares | Average price / share | Total cost |
| 15.9.2026 | 11,618 | 9.3623 | 108,771.20 |
| 16.9.2026 | 11,633 | 9.4672 | 110,131.94 |
| 17.9.2026 | 12,119 | 9.6450 | 116,887.76 |
| 18.9.2026 | 12,190 | 9.5990 | 117,011.81 |
| Total amount, week 38 | 47,560 | 9.5207 | 452,802.71 |
Marimekko Corporation now holds a total of 133,460 shares including the shares repurchased on 18 September 2026.
On 14 September 2026, Marimekko announced that it will start acquiring the company’s own shares based on the authorization granted by the Annual General Meeting held on 16 April 2026. The repurchase of own shares is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.
Details of the transactions are included as an appendix of this announcement.
On behalf of Marimekko Corporation
EVLI OYJ
Aleksi Jalava
Further information:
Anna Tuominen
tel. +358 40 584 6944
anna.tuominen@marimekko.com
DISTRIBUTION:
Nasdaq Helsinki Ltd
Key media
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
Orion Oyj18.9.2026 18:00:00 CEST | Press release
Orion Corporation: Acquisition of own shares during week 38, 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom